This week, Fulcrum Therapeutics announced results from an interim analysis of data collected from its Phase 2 ReDUX4 trial, which is testing the effect of a drug called losmapimod in individuals with facioscapulohumeral muscular dystrophy (FSHD). The drug, which is taken as a pill twice a day, is intended to reduce the expression of a… Read More »
Fulcrum’s interim findings from ReDUX4 trial are “encouraging”
FSHD Clinical Trial Research Network expands to four new sites
The FSHD Society announced today that it has awarded $300,000 a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on funding of $300,000 a year in 2021 and 2022. The network is a consortium of academic research centers in the United States and Europe with expertise in FSHD clinical… Read More »
Help us grow our network
The future is in YOUR hands The FSHD community has an urgent challenge and a powerful opportunity to help support research studies and upcoming clinical trials. Currently, there are nearly a dozen very promising drug candidates. One is already being tested in patients. Others are in earlier stages. We are more hopeful than ever before… Read More »
ReDUX4 clinical trial update
In this video, Diego Cadavid, MD, Senior Vice President, Clinical Development, at Fulcrum Therapeutics provides an update on ReDUX4, the Phase 2b clinical trial currently underway testing the safety and efficacy of losmapimod to treat facioscapulohumeral muscular dystrophy (FSHD). The company started recruiting volunteers for the trial in August of 2019 and completed enrollment in… Read More »
Tips and tricks: Pencil grips
If you’re hand grip has weakened, here’s a product that could be helpful. Originally designed to help children grip a pencil properly, these pencil grips are manufactured from soft silicone with perforations to keep your skin comfortable. The manufacturer states that this “pencil gripper can be used by children, adults or the old with arthritis… Read More »